Cedar Mountain Advisors
TGTX icon

Cedar Mountain Advisors’s TG Therapeutics TGTX Stock Holding History

Cedar Mountain Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$558 Hold
10
– – ﹤0.01% 1001
2026
Q2 		$549 Buy
+10
New +$409 ﹤0.01% 1036
2026
Q1 		– Sell
-1
Closed -$30 – 1205
2025
Q4 		$30 Buy
+1
New +$33 ﹤0.01% 734

Other funds holding TGTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Penn Capital Management
Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Cedar Mountain Advisors's TGTX Position: Q3 2026 in Review

Cedar Mountain Advisors held its TG Therapeutics (TGTX) position steady in Q3 2026 at 10 shares worth $558. The position accounts for ﹤0.01% of the portfolio, ranked #1001.

Cedar Mountain Advisors first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • Cedar Mountain Advisors held 10 shares of TG Therapeutics worth $558 as of Q3 2026.
  • Cedar Mountain Advisors left its TG Therapeutics share count unchanged in Q3 2026.
  • TG Therapeutics made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #1001 holding.
  • Cedar Mountain Advisors first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.